Medipattern Encouraged by Growth in Vascular Volumes

Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern" or the "Company") (TSX VENTURE:MKI),
a pioneer in the development of medical imaging software solutions that help
medical practitioners to better understand lesions and critical anatomy,
continues to grow market share for Visualize:Vascular(TM) 3D rendering of the
lumen in carotid arteries.


"Medical products need to be validated on three levels to gain market
acceptance: 1 - clinical benefit, 2 - reimbursement and 3 - workflow.
Visualize:Vascular has been validated on all three points," commented Jeff
Collins, CEO of Medipattern. "First and foremost, medical facilities need to be
able to determine the clinical impact of the new diagnostic tool. The white
paper(1) and case studies(2, 3) have demonstrated that Visualize:Vascular
assists a doctor through its 3D perspective and automated luminal measurements.
It has received reimbursement from most major payers. Visualize:Vascular has
been shown to be easy to introduce in practice with our installed base. The
special cine scan only takes a few minutes and fits well within the standard
carotid duplex exam workflow. We have used the product launch phase to validate
the product in all three categories. Market share has increased dramatically for
Visualize:Vascular. It is encouraging to see that our scanning volumes are
steadily increasing week over week. It takes time for all the centers to come up
to full volume. We are seeing continued growth in usage volumes as each center
goes through the process of installation, training, introduction of the service
to referring physicians, and changing order forms to enable using
Visualize:Vascular 3D rendering in standard practice," Collins concluded.


We welcome East River Radiology, with four locations in Manhattan, MD&T of New
Jersey: a mobile ultrasound provider with 48 mobile entities, Northshore Primary
Care part of the Healthbridge Network with four sites on Long Island, Advanced
Radiological Imaging with two locations in New York City and Zwanger-Pesiri
Radiology with nine locations on Long Island.


Please visit "our solutions" at www.medipattern.com to see all of our product
updates.


(1) Francis Porreca, MD, FACS, RVPI, Angela Rodriguez-Wong, MD, RVT, RVPI, JP
Hughes RVS, RVT, "Three Dimensional Reconstruction of the Vessel Lumen as an
Adjunct to the Cerebrovascular Duplex Evaluation" SVU June 2011


(2) Francis Porreca, MD, FACS, RVPI, Angela Rodriguez-Wong, MD, RVT, RVPI, "Case
Study: 71 yr old male with bilateral Bruit"
http://www.medipattern.com/solutions_vascular_casestudy1.aspx


(3) Daniel Gurell, MD, "Case Study: 71 yr old asymptomatic male"
http://www.medipattern.com/solutions_vascular_casestudy2.aspx




Upcoming Events                                                             
The Breast Course              April 15 - 18, 2012      Lisbon, Portugal    
CAR Annual Meeting             April 26 - 29, 2102      Montreal, Quebec    
Annual Meeting - MHA           June 6 - 7, 2012         Brewster, MA        
SVU/SVS Annual Conference      June 7 - 9, 2012         Baltimore, MD       



About the Medipattern Corporation:

Medipattern(R) is a pioneer in the development of imaging software solutions
that help medical practitioners to better understand lesions and critical
anatomy. Medipattern uses its Cadenza(TM) technology to process images, finding
the salient region of interest and presenting them in 2D and 3D formats that
enhance the reader's perception. For more information, please visit the
Company's website: www.medipattern.com.


Medipattern(R) and B-CAD(R) are registered trademarks of The Medipattern
Corporation. Visualize:Vascular(TM) and Cadenza(TM) are trademarks of the
Medipattern Corporation. SonoCine is a registered trademark of SonoCine, Inc.


Forward-looking statements

This document contains forward-looking statements relating to Medipattern's
performance, operations, or business environment. These statements are based on
what we believe are reasonable assumptions given currently available information
and our understanding of Medipattern's current activities. We have tried,
whenever possible, to identify these forward-looking statements using words such
as "anticipates," "believes," "estimates," "expects," "plans," "intends,"
"potential", and similar expressions. Forward-looking statements are not
guarantees of future performance and involve risks and uncertainties that are
difficult to predict or control. A number of factors could cause actual outcomes
and results to differ materially from those expressed in forward-looking
statements. These factors include but are not limited to those set forth in the
Company's corporate filings, (posted at www.sedar.com). In addition, these
forward-looking statements relate to the date on which they are made. The
Company disclaims any intention or obligation to update or revise any
forward-looking statements for any reason. Readers should not rely on
forward-looking statements.